Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Giovanna De Luca

Multiple Sclerosis Centre Medical Coordinator (responsabile Centro SM con incarico di medio alta professionalità)

Ospedale San Raffaele

Italy

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Virology

40%

Epidemiology

50%

Multiple Sclerosis

90%

Systemic Sclerosis

60%

Covid-19

50%

Sars-cov-2

30%

Antiviral Therapy

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles23

Effect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study

Article Link

Year:

2025

Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies

Article Link

Year:

2025

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

Article Link

Year:

2024

Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

Article Link

Year:

2024

Late-onset multiple sclerosis: disability trajectories in relapsing–remitting patients of the Italian MS Registry

Article Link

Year:

2024

Multiple Sclerosis Progression and Relapse Activity in Children

Article Link

Year:

2024

Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis

Article Link

Year:

2024

Registers as Central Real World Data Source: The Experience of the Italian Multiple Sclerosis and Related Disorders Register,I registri come importante fonte di real world data: l’esperienza del Registro Italiano Sclerosi Multipla e Patologie Correlate

Article Link

Year:

2024

Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.

Article Link

Year:

2024

Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

Article Link

Year:

2024

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

Article Link

Year:

2023

Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey

Article Link

Year:

2023

A score that predicts <scp>aquaporin‐4 IgG</scp> positivity in patients with longitudinally extensive transverse myelitis

Article Link

Year:

2023

Predicting sense of coherence among caregiving partners of persons with multiple sclerosis.

Article Link

Year:

2023

Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

Article Link

Year:

2023

Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs

Article Link

Year:

2023

Sars-CoV2 infection in pregnant women with multiple sclerosis

Article Link

Year:

2023

Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge

Article Link

Year:

2023

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

Article Link

Year:

2023

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Article Link

Year:

2023

COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients

Article Link

Year:

2023

Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey.

Article Link

Year:

2023

Signs and symptoms of COVID‐19 in patients with multiple sclerosis

Article Link

Year:

2022

Collaborators20

Vilija Jokubaitis

MONASH UNIVERSITY

AUSTRALIA

Sara Mariotto

ITALY

Paola Mosconi

Head of Laboratory

Istituto di Ricerche Farmacologiche Mario Negri IRCCS

ITALY

Massimiliano Di Filippo

Università degli Studi di Perugia Dipartimento di Scienze Farmaceutiche

ITALY

Justin Yehuda Garber

Clinical Senior Lecturer

University of Sydney

AUSTRALIA

Marco Vercellino

ITALY

Mark Slee

Flinders University

AUSTRALIA

Marzena Pedrini

University of Western Australia

AUSTRALIA

Pietro Iaffaldano

Associate Professor of Neurology

University of Bari Aldo Moro

ITALY

Eduardo Aguera-Morales

Profesor Asociado

Universidad de Córdoba

SPAIN

Antonella Conte

Sapienza University of Rome

ITALY

Raffaele Iorio

ITALY

Matteo Minetti

University of Genoa

ITALY

Paolo Ragonese

University of Palermo

ITALY

Luca Negri

Tenure Track Assistant Professor (PSIC-01/A - Psicologia Generale)

University of Milano-Bicocca

ITALY

Pasquale Paletta

Istituto di Ricerche Farmacologiche Mario Negri

ITALY

Allan Kermode

University of Western Australia

AUSTRALIA

Emilio Portaccio

University of Florence

ITALY

Silvia Romano

Università degli Studi di Roma La Sapienza

ITALY

William L Herring

Health Solutions

UNITED STATES

How do I reach out?

Meet Kite AI